Surgery for pancreatic cancer: current controversies and challenges

被引:41
作者
Karunakaran, Monish [1 ,2 ]
Barreto, Savio George [3 ,4 ]
机构
[1] Medanta Medicity, Dept Gastrointestinal Surg Gastrointestinal Oncol, Medanta Inst Digest & Hepatobiliary Sci, Gurugram 122001, India
[2] Medanta Medicity, Dept Liver Transplantat & Regenerat Med, Gurugram 122001, India
[3] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
[4] Flinders Med Ctr, Div Surg & Perioperat Med, Adelaide, SA, Australia
关键词
extended pancreatectomy; lymphadenectomy; minimally invasive pancreatic surgery; neoadjuvant therapy; pancreatic cancer; vascular resections; CELIAC AXIS RESECTION; MESENTERIC VEIN RESECTION; LYMPH-NODE RATIO; INTERNATIONAL STUDY-GROUP; LAPAROSCOPIC DISTAL PANCREATECTOMY; RANDOMIZED CLINICAL-TRIAL; LEFT GASTRIC ARTERY; LONG-TERM SURVIVAL; EN-BLOC RESECTION; PORTAL-VEIN;
D O I
10.2217/fon-2021-0533
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Two main areas of focus in pancreatic cancer research are the high rates of post-surgery complications and poor survival despite completely removing the tumor. Complete, margin-negative resection (where some healthy tissue is removed to ensure the whole tumor is cut out) is the only way to ensure long-term survival. However, such extensive resections, especially when they involve nearby blood vessels and/or organs, should only be undertaken if the imaging done pre-surgery indicates the possibility that a complete, margin-negative resection can be achieved. It should be noted that the removal of lymph nodes, in addition to the ones normally removed during a pancreatic resection, does not confer a survival benefit. Distal pancreatectomy (performed for tumors involving the body or tail of the pancreas) is safe and feasible using minimal access methods; however, the safety of minimally-invasive pancreatoduodenectomy (performed for tumors of the head of the pancreas) remains to be proven. The oncological benefit of minimally-invasive distal pancreatectomy over open surgery has not been established. Two areas that remain the focus of improvement in pancreatic cancer include high post-operative morbidity and inability to uniformly translate surgical success into long-term survival. This narrative review addresses specific aspects of pancreatic cancer surgery, including neoadjuvant therapy, vascular resections, extended pancreatectomy, extent of lymphadenectomy and current status of minimally invasive surgery. R0 resection confers longer disease-free survival and overall survival. Vascular and adjacent organ resections should be undertaken after neoadjuvant therapy, only if R0 resection can be ensured based on high-quality preoperative imaging, and that too, with acceptable post-operative morbidity. Extended lymphadenectomy does not offer any advantage over standard lymphadenectomy. Although minimally invasive distal pancreatectomies offers some short-term benefits over open distal pancreatectomy, safety remains a concern with minimally invasive pancreatoduodenectomy. Strict adherence to principles and judicious utilization of surgery within a multimodality framework is the way forward.
引用
收藏
页码:5135 / 5162
页数:28
相关论文
共 50 条
  • [41] Current Controversies in the Management of Colon Cancer
    不详
    [J]. CURRENT PROBLEMS IN SURGERY, 2012, 49 (07) : 398 - 460
  • [42] Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment
    Klaiber, Ulla
    Hackert, Thilo
    [J]. FRONTIERS IN ONCOLOGY, 2020, 9
  • [43] Minimally invasive surgery for pancreatic cancer
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Nakamura, Masafumi
    [J]. SURGERY TODAY, 2021, 51 (02) : 194 - 203
  • [44] Pancreatic cancer indications for and radicality of surgery
    Keck, T.
    [J]. ONKOLOGE, 2010, 16 (06): : 28 - +
  • [45] Optimizing the outcomes of pancreatic cancer surgery
    Strobel, Oliver
    Neoptolemos, John
    Jaeger, Dirk
    Buechler, Markus W.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (01) : 11 - 26
  • [46] Fifty Years of Surgery for Pancreatic Cancer
    Hackert, Thilo
    Klaiber, Ulla
    Pausch, Thomas
    Mihaljevic, Andre L.
    Buechler, Markus W.
    [J]. PANCREAS, 2020, 49 (08) : 1005 - 1013
  • [47] Conversion Surgery for Advanced Pancreatic Cancer
    Hank, Thomas
    Strobel, Oliver
    [J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [48] Advances and challenges of neoadjuvant therapy in pancreatic cancer
    Yu, Yang
    Zheng, Peng
    Chen, Yajing
    Wang, Bofang
    Paul, Maswikiti Ewetse
    Tao, Pengxian
    Wang, Dengfeng
    Li, Haiyuan
    Gu, Baohong
    Gao, Lei
    Wang, Dan
    Chen, Hao
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (06) : 425 - 434
  • [49] How to treat borderline resectable pancreatic cancer: current challenges and future directions
    Takahashi, Shinichiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (03) : 205 - 213
  • [50] Surgical resection of pancreatic head cancer: What is the optimal extent of surgery?
    Kang, Mee Joo
    Jang, Jin-Young
    Kim, Sun-Whe
    [J]. CANCER LETTERS, 2016, 382 (02) : 259 - 265